Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation

Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation is organized by PeerView Institute for Medical Education (PVI), Medical College of Wisconsin (MCW) and will be held from Apr 02, 2019 - Apr 01, 2020.

Target Audience:
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of patients with leukemia and lymphoma.

Accreditation:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Description and Educational Objectives:
In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experiences from their practice or research on relevant patient cases to guide learners on how to effectively impact treatment care and improve outcomes for patients with leukemia and lymphoma.

Upon completion of this activity, participants should be better able to:
• Summarize the anticancer mechanism and the latest evidence on the efficacy and safety of adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in various lymphoma and leukemia settings
• Assess the clinical role and benefits of CAR-T cell therapy within the context of HCT in eligible patients with leukemia and lymphoma
• Apply appropriate strategies to manage the unique safety issues associated with CAR-T cell therapy in leukemia and lymphoma.